主页 > 医药生命 >
【drug-news】辉瑞剥离资产成立新的生物技术公司
Pfizer has spun of Esperion Therapeutics into a new biotech company aiming to develop new therapies for cardiovascular and metabolic disease. A syndicate of investors funded the deal. Pfizer sold its interests in the former subdivision to Esperion, which raised $22.75 million from venture funds to finance its operations. Financial details on the spin-off were not disclosed. Pfizer retains an interest in the company.
"Pfizer's contribution to the formation of the new Esperion shows the Company is embracing new strategies to refocus its R&D and create value from exited compounds," said Martin Mackay, president of Pfizer Global Research & Development. "This transaction also enables Esperion to pursue its interests as a Michigan-based life science company while allowing Pfizer to support a new research venture and be involved in Esperion's potential success."
Aisling Capital, Alta Partners and Domain Associates co-led the tranched financing for Esperion, with Arboretum Ventures joining in. The new money will allow further development of Esperion's lead program for the treatment of dyslipidemias, as well as other HDL-related therapeutics. 本人已认领该文翻译，48小时后若未提交译文，请其他战友自由认领 Pfizer has spun off Esperion Therapeutics into a new biotech company aiming to develop new therapies for cardiovascular and metabolic disease. A syndicate of investors funded the deal. Pfizer sold its interests in the former subdivision to Esperion, which raised $22.75 million from venture funds to finance its operations. Financial details on the spin-off were not disclosed. Pfizer retains an interest in the company.
Esperion Therapeutics （ESPR）从辉瑞剥离，成为一个新的生物技术公司，其目标是研发新的心血管和代谢性疾病方面的药物。投资者辛迪加资助该交易。辉瑞为这次运作募捐到22,750,000美金的风险资金，同时它会将利润一级一级分配到Esperion。此次运作的财政细节并没有公布，不过辉瑞仍然会取得部分利润。
"Pfizer's contribution to the formation of the new Esperion shows the Company is embracing new strategies to refocus its R&D and create value from exited compounds," said Martin Mackay, president of Pfizer Global Research & Development. "This transaction also enables Esperion to pursue its interests as a Michigan-based life science company while allowing Pfizer to support a new research venture and be involved in Esperion's potential success."
辉瑞全球研发部总裁Martin Mackay说：“辉瑞对新Esperion公司的形成所产生的作用显示了辉瑞将采用新的策略－重新关注自己的研发和从外叶化合物中创造价值。”接着说道：“这种变动使Esperion能够像密歇根生命科学公司那样追求自己的利润，同时也使辉瑞能够支持新的研发和专注于Esperion潜在的成功。”
Aisling Capital, Alta Partners and Domain Associates co-led the tranched financing for Esperion, with Arboretum Ventures joining in. The new money will allow further development of Esperion's lead program for the treatment of dyslipidemias, as well as other HDL-related therapeutics.
Aisling Capital， Alta Partners ， Domain Associates 和Arboretum Ventures（生物技术风险投资公司）共同操作Esperion公司的资金份额。这笔资金将用于Esperion公司关于血脂代谢障碍和其他高密度脂蛋白相关治疗法等前沿计划的长足发展。 相关资料1：
May 01, 2008 08:30 AM Eastern Daylight Time
Esperion Therapeutics Completes $22.75 M Series A Financing
Pfizer Inc Spinout of Esperion Therapeutics - Founding Team to Focus on HDL Therapies As a Private Entity
ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular and metabolic disease, today announced that it has been launched as a privately held, independent enterprise.
Pfizer Inc, under which Esperion previously operated as a separate research division, has sold Esperion Therapeutics, holding selected programs and related assets, to an entity funded by a syndicate of investors. Pfizer retains a financial interest in the enterprise. Additional financial details of the transaction were not disclosed.
Co-led by Aisling Capital, Alta Partners and Domain Associates, the tranched financing for Esperion also included participation by Arboretum Ventures. This support will allow further development of the Company’s lead program for the treatment of dyslipidemias, as well as other potentially high density lipoprotein (HDL)-related therapeutics.
Esperion Therapeutics will be led by Dr. Roger Newton, the original co-founder, CEO and President of the Company. Esperion will continue to leverage the scientific expertise and resources that reside in its Ann Arbor, Mich., headquarters. As part of the spinout from Pfizer, Esperion will retain a small molecule dual inhibitor of fatty acid and cholesterol synthesis, for the treatment of dyslipidemias.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-10 17:11
医学,生命科学网